I think this FTSE 100 share’s hidden value is set to be outed

G A Chester discusses a FTSE 100 (INDEXFTSE:UKX) stock he thinks is undervalued by 50%+.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’m always interested in companies with potential to deliver value for shareholders by way of a spin-off, or other divestment strategy. I don’t mean distressed companies selling assets out of desperation. I’m talking about sound businesses, capable of performing well as they are, but with options to divest subsidiary assets or divisions to maximise the value of the parent company.

Industrial technologies conglomerate Smiths Group (LSE: SMIN) is one such FTSE 100 stock on my radar right now. Here, I’ll look at how it’s performing, its potential for unlocking value by divestments, and why I think its shares are undervalued by 50%+.

Hidden value highlighted

Smiths Group has made steady progress in sharpening its portfolio of businesses since a change of management in 2015. It caught my eye last September after news it had turned down an offer for its Smiths Medical division, reportedly in the region of £2.5bn-£2.8bn.

This highlights there may be considerable hidden value in the group. The table below shows some key numbers for its five divisions from its last financial year.

  Revenue (£m) Underlying operating profit (£m) Underlying operating margin (%)
Smiths Medical 885 156 17.6
John Crane 881 202 22.9
Smiths Detection 793 134 16.9
Flex-Tek 354 67 18.9
Smiths Interconnect 300 42 14.1
Total 3,213 601 18.7

Smiths Medical accounted for 27.5% of group revenue and 26% of group underlying operating profit. How much might the whole group be worth? On the basis of that £2.5bn-£2.8bn reported offer — 26% of group operating profit — we might value the whole group at between £9.6bn and £10.8bn (2,425p to 2,728p per share). Yet its market capitalisation is currently just £6.5bn, with the shares trading at 1,640p.

A comparative valuation

Could Smiths really be worth so much more than its current valuation? Intertek, a highly rated FTSE 100 peer, has a similar underlying operating margin to Smiths. And I consider they share some broad drivers for long-term growth, as well as similar near-term forecast earnings growth rates, according to City analysts.

Smiths currently trades on 15.8 times forecast 12-month earnings, while Intertek’s multiple is 25.9. If Smiths were to be afforded the same multiple as Intertek, it would be valued at a little under £10.7bn (2,697p a share) — within, and at the top end of, the valuation range I derived from the rejected offer for Smiths Medical.

Unlocking the value

In November last year, two months after rejecting the offer, the company announced its “intention to separate Smiths Medical.” By March this year, this had become an “intention to pursue a demerger of the Smiths Medical business and separately list it in the UK.” Management said it anticipates completing the process during the first half of calendar 2020, subject to the approval of shareholders.

As my colleague Kevin Godbold has discussed, the separation into two companies promises to give each “greater and more-focused entrepreneurial drive.” As such, I expect shareholders to strongly approve of the demerger.

In the meantime, there’s always the possibility of another (higher) bid for Smiths Medical, or some other value-outing event, as “the board will continue to evaluate all opportunities for value maximisation as the process goes forward.”

Based on my valuation calculations, I think investors at today’s share price should enjoy strong returns, as events unfold. I expect significant value to be unlocked in due course. I rate the stock a ‘buy’.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has recommended Intertek. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »